Catalio Capital Management

Founded 2016

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 15
Average round size
info
The average size of a deal this fund participated in
$94M
Portfolio companies 15
Rounds per year 3.00
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Life Science
  • Therapeutics
  • Artificial Intelligence

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Entos

Artificial Intelligence
Machine Learning
Software
$53M14 Jul 2021 Los Angeles, California, United States

Biotechnology
Medical
$32M06 Apr 2021 New York, New York, United States

ATAI Life Sciences

Biotechnology
Health Care
Life Science
Therapeutics
$157M03 Mar 2021 Bavaria

Immunai

Artificial Intelligence
Biotechnology
Machine Learning
Therapeutics
$60M11 Feb 2021 New York, United States

Personal Genome Diagnostics

Analytics
Bioinformatics
Biotechnology
Genetics
Health Diagnostics
Medical
$103M10 Feb 2021 Baltimore, Maryland, United States

Cambrian Biopharma

Biopharma
Biotechnology
Life Science
$60M09 Feb 2021 New York, New York, United States

SetPoint Medical

Biotechnology
Health Care
Medical Device
Neuroscience
$64M27 Jan 2021 Santa Clarita, California, United States

Paige

Artificial Intelligence
Biopharma
Health Care
Health Diagnostics
Software
$125M14 Jan 2021 New York, New York, United States

Sensei Biotherapeutics

Biotechnology
Health Diagnostics
Life Science
Medical
Therapeutics
$30M11 Jan 2021 Maryland, United States
News
DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform

– DNA Script announced it has raised $165m in a Series C financing round.
– The round was led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
– The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
– The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.

Entos Raises $53 Million Series A Round Led by Coatue and Catalio

– Entos, Inc. (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, announced the closing of a $53 million Series A.
– The financing round was led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Catalio Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: